FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973286979> ?p ?o ?g. }

• W1973286979 endingPage "322" @default.
• W1973286979 startingPage "315" @default.
• W1973286979 abstract "Resistance of cancer to chemotherapy remains a challenging issue for scientists as well as physicians. Naturally occurring xanthones possess a variety of biological activities such as anti-inflammatory, anti-bacterial, and anti-cancer effects. The present study was aimed at investigating the cytotoxicity and the modes of action of three naturally occurring xanthones namely, morusignin I (1), 8-hydroxycudraxanthone G (2) and cudraxanthone I (3) against a panel of nine cancer cell lines, including various sensitive and drug-resistant phenotypes. The cytotoxicity of the compounds was determined using a resazurin reduction assay, whereas the caspase-Glo assay was used to detect the activation of caspases 3/7, caspase 8 and caspase 9 in cells treated with compounds 3. Flow cytometry was used for cell cycle analysis and detection of apoptotic cells, analysis of mitochondrial membrane potential (MMP) as well as measurement of reactive oxygen species (ROS). Compounds 1 and 3 inhibited the proliferation of all tested cancer cell lines including sensitive and drug-resistant phenotypes. Compound 2 was active on 8/9 cell lines with the IC50 values ranging from 16.65 μM (against leukemia CCRF-CEM cells) to 70.38 μM (against hepatocarcinoma HepG2 cells). The IC50 value ranged from 7.15 μM (against CCRF-CEM cells) to 53.85 μM [against human glioblastoma U87MG.ΔEGFR cells] for compound 1, and from 2.78 μM (against breast cancer MDA-MB231 BCRP cells) to 22.49 μM (against U87MG cells) for compound 3. P-glycoprotein expressing CEM/ADR5000 cells were cross-resistant to compounds 1 and 2 (4.21- to 610-fold) while no cross-resistance or even collateral cross-sensitivity were observed in other drug-resistant cell lines to the three compounds. Normal AML12 liver cells were more resistant to the three compounds than HepG2 liver cancer cells. Compounds 3 arrested the cell cycle between G0/G1 and S phases, strongly induced apoptosis via caspases 3/7, caspase 8, caspase 9 activation and disrupted the MMP in CCRF-CEM cells. The cytotoxicity of the studied xanthones and especially compound 3 deserve more detailed exploration in the future to develop novel anticancer drugs against sensitive and otherwise drug-resistant phenotypes." @default.
• W1973286979 created "2016-06-24" @default.
• W1973286979 creator A5025455472 @default.
• W1973286979 creator A5050551827 @default.
• W1973286979 creator A5052484109 @default.
• W1973286979 creator A5052981792 @default.
• W1973286979 creator A5074274406 @default.
• W1973286979 creator A5087995617 @default.
• W1973286979 date "2014-02-01" @default.
• W1973286979 modified "2023-10-01" @default.
• W1973286979 title "Cytotoxicity and modes of action of three naturally occurring xanthones (8-hydroxycudraxanthone G, morusignin I and cudraxanthone I) against sensitive and multidrug-resistant cancer cell lines" @default.
• W1973286979 cites W1974907920 @default.
• W1973286979 cites W1981106016 @default.
• W1973286979 cites W1985262744 @default.
• W1973286979 cites W1996594797 @default.
• W1973286979 cites W1996599332 @default.
• W1973286979 cites W2002716364 @default.
• W1973286979 cites W2017127543 @default.
• W1973286979 cites W2027682810 @default.
• W1973286979 cites W2030608160 @default.
• W1973286979 cites W2033222884 @default.
• W1973286979 cites W2041294276 @default.
• W1973286979 cites W2049231245 @default.
• W1973286979 cites W2049626094 @default.
• W1973286979 cites W2053373547 @default.
• W1973286979 cites W2055904567 @default.
• W1973286979 cites W2061701210 @default.
• W1973286979 cites W2070966969 @default.
• W1973286979 cites W2072227776 @default.
• W1973286979 cites W2075054009 @default.
• W1973286979 cites W2083190417 @default.
• W1973286979 cites W2086125907 @default.
• W1973286979 cites W2088415033 @default.
• W1973286979 cites W2117816508 @default.
• W1973286979 cites W2134174082 @default.
• W1973286979 cites W2138935969 @default.
• W1973286979 cites W2142024216 @default.
• W1973286979 cites W2142777712 @default.
• W1973286979 cites W2143006671 @default.
• W1973286979 cites W2154385453 @default.
• W1973286979 cites W2399475545 @default.
• W1973286979 doi "https://doi.org/10.1016/j.phymed.2013.08.018" @default.
• W1973286979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24075210" @default.
• W1973286979 hasPublicationYear "2014" @default.
• W1973286979 type Work @default.
• W1973286979 sameAs 1973286979 @default.
• W1973286979 citedByCount "79" @default.
• W1973286979 countsByYear W19732869792014 @default.
• W1973286979 countsByYear W19732869792015 @default.
• W1973286979 countsByYear W19732869792016 @default.
• W1973286979 countsByYear W19732869792017 @default.
• W1973286979 countsByYear W19732869792018 @default.
• W1973286979 countsByYear W19732869792019 @default.
• W1973286979 countsByYear W19732869792020 @default.
• W1973286979 countsByYear W19732869792021 @default.
• W1973286979 countsByYear W19732869792022 @default.
• W1973286979 countsByYear W19732869792023 @default.
• W1973286979 crossrefType "journal-article" @default.
• W1973286979 hasAuthorship W1973286979A5025455472 @default.
• W1973286979 hasAuthorship W1973286979A5050551827 @default.
• W1973286979 hasAuthorship W1973286979A5052484109 @default.
• W1973286979 hasAuthorship W1973286979A5052981792 @default.
• W1973286979 hasAuthorship W1973286979A5074274406 @default.
• W1973286979 hasAuthorship W1973286979A5087995617 @default.
• W1973286979 hasConcept C109316439 @default.
• W1973286979 hasConcept C121608353 @default.
• W1973286979 hasConcept C133936738 @default.
• W1973286979 hasConcept C153911025 @default.
• W1973286979 hasConcept C185592680 @default.
• W1973286979 hasConcept C190283241 @default.
• W1973286979 hasConcept C202751555 @default.
• W1973286979 hasConcept C2778400546 @default.
• W1973286979 hasConcept C29537977 @default.
• W1973286979 hasConcept C501593827 @default.
• W1973286979 hasConcept C502942594 @default.
• W1973286979 hasConcept C54355233 @default.
• W1973286979 hasConcept C553184892 @default.
• W1973286979 hasConcept C55493867 @default.
• W1973286979 hasConcept C81885089 @default.
• W1973286979 hasConcept C86803240 @default.
• W1973286979 hasConcept C96232424 @default.
• W1973286979 hasConceptScore W1973286979C109316439 @default.
• W1973286979 hasConceptScore W1973286979C121608353 @default.
• W1973286979 hasConceptScore W1973286979C133936738 @default.
• W1973286979 hasConceptScore W1973286979C153911025 @default.
• W1973286979 hasConceptScore W1973286979C185592680 @default.
• W1973286979 hasConceptScore W1973286979C190283241 @default.
• W1973286979 hasConceptScore W1973286979C202751555 @default.
• W1973286979 hasConceptScore W1973286979C2778400546 @default.
• W1973286979 hasConceptScore W1973286979C29537977 @default.
• W1973286979 hasConceptScore W1973286979C501593827 @default.
• W1973286979 hasConceptScore W1973286979C502942594 @default.
• W1973286979 hasConceptScore W1973286979C54355233 @default.
• W1973286979 hasConceptScore W1973286979C553184892 @default.
• W1973286979 hasConceptScore W1973286979C55493867 @default.
• W1973286979 hasConceptScore W1973286979C81885089 @default.
• W1973286979 hasConceptScore W1973286979C86803240 @default.
• W1973286979 hasConceptScore W1973286979C96232424 @default.

• next